Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase

8 Jul 2014

Abstract excerpt

BACKGROUND: Topoisomerase I (Topo I) poisons (e.g., camptothecin (CPT)), used to treat cancer, cause DNA breaks that are most cytotoxic during S phase. PARP-1 promotes DNA repair and PARP inhibitors (PARPi) sensitise cells to Topo I poisons. We aimed to determine whether chemosensitisation is also S phase specific using rucaparib, a potent PARPi in advanced clinical evaluation. METHODS: The impact of rucaparib,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25003660
DOI: 10.1038/bjc.2014.378

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phasePMID 25003660Read ↗

Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status.Semantic proximity Read ↗

DNA Repair and Resistance to Topoisomerase I Inhibitors: Mechanisms, Biomarkers and Therapeutic TargetsSemantic proximity Read ↗

Hyperthermia Synergizes with Chemotherapy by Inhibiting PARP1-Dependent DNA Replication ArrestSemantic proximity Read ↗

The Current Status of Camptothecin Analogues as Antitumor AgentsSemantic proximity Read ↗

DNA polymerase α-primase facilitates PARP inhibitor-induced fork acceleration and protects BRCA1-deficient cells against ssDNA gapsSemantic proximity Read ↗

Recent developments in topoisomerase-targeted cancer chemotherapySemantic proximity Read ↗

Targeting topoisomerase I: molecular mechanisms and cellular determinants of response to topoisomerase I inhibitorsSemantic proximity Read ↗

The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates the Effects of Topoisomerase I Poisons by Suppressing Rad51 Expression in a p53-Dependent MannerSemantic proximity Read ↗

CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons <i>In vitro</i> and <i>In vivo</i>Semantic proximity Read ↗

PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNASemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.